On April 9, 2021 ONCURIOUS NV, a Belgium-based biotech company focused on developing innovative oncology treatments, reported that it will make two presentations at the upcoming AACR (Free AACR Whitepaper) Virtual Annual Meeting 2021 which will take place from 9 to 14 April (Press release, Oncurious, APR 9, 2021, View Source,from%209%20to%2014%20April. [SID1234577793]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The first of these is an oral presentation of data from a Phase 1 dose escalation study of TB-403, a humanized monoclonal antibody against placental growth factor (PlGF), in pediatric cancer subjects for treatment of medulloblastoma:

Title: A Phase 1, open label, multicenter, dose escalation study of TB-403 in pediatric subjects with relapsed or refractory medulloblastoma, neuroblastoma, Ewing Sarcoma or alveolar rhabdomyosarcoma

Presented by: Dr. Giselle Sholler, Director at the Isabella Santos Foundation Solid and Rare Tumor Program, Chair at Beat Childhood Cancer Research Consortium, and Professor, Pediatric Oncology at the Levine Children’s Hospital in Charlotte, NC.

Presentation #: CT015

Session Title: Early Clinical Trials with New Anticancer Agents

Session Date and Time: Saturday 10th April from 1:30 PM to 3:30 PM US EDT

The second presentation is an e-poster presentation of preclinical data:

Title: Investigation of the best therapeutic approach to target CCR8 expressed on tumor regulatory T cells to boost anti-tumor immune responses

Authors: Heleen Roose, Elizabeth Allen, Helena Van Damme, Bruno Dombrecht, Rosa Martín-Pérez, Damya Laoui, Jo A. Van Ginderachter, Pascal Merchiers. Oncurious NV, Leuven, Belgium, Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel and Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium, VIB Discovery Sciences, Leuven-Ghent, Belgium.

Date and Time: The e-poster will be available on AACR (Free AACR Whitepaper)’s website on Saturday 10th April at 8:30 AM US EDT (the first day of the virtual AACR (Free AACR Whitepaper) Annual Meeting). The e-poster will remain available for viewing through to Monday 21st June 2021.

The abstract can be viewed here.

In February 2021, The Journal for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (a BMJ journal) published a paper on the efficacy and safety of targeting CCR8 for the depletion of tumor-promoting tumor infiltrating Tregs in combination with anti-PD-1 therapy. For more information please see Oncurious press release here.

On April 9, 2021 Bold Therapeutics, a clinical-stage biopharmaceutical company developing BOLD-100, a first-in-class anti-cancer agent, reported that Sandra Van Schaeybroeck, PhD (Queen’s University Belfast) will be presenting research supporting BOLD-100 as a potential anti-resistance therapy for difficult-to-treat cancers, specifically BRAF-mutant colorectal cancer (Press release, Bold Therapeutics, APR 9, 2021, View Source [SID1234577809]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Van Schaeybroeck’s AACR (Free AACR Whitepaper) poster presentation "Targeting the DNA repair pathway with BOLD-100 in BRAF-mutant colorectal cancer" (Poster# 1183, Session PO.ET04.03 on April 10) highlights the promising research conducted by the Drug Resistance Group at the Patrick G. Johnston Centre for Cancer Research at Queen’s University Belfast, which investigated BOLD-100’s mechanism-of-action and identified promising treatment combinations in difficult-to-treat BRAF-mutant colorectal cancers.

Colon cancer is one of the most frequently diagnosed malignancies in adults, responsible for approximately 11% of all new cases of cancers worldwide and one-third of cancer deaths. BRAF-mutant colorectal cancers comprise 10% of those patients, and this subgroup has morphological, clinical, and therapeutic characteristics that differ substantially from patients without this genetic alteration. Importantly, there is no established standard of care for BRAF-mutant colorectal cancer, which is associated with a particularly poor prognosis and a median OS of less than 12 months versus more than 30 months for BRAF wild type metastatic colorectal cancer (mCRC), with V600E BRAF-mutated colorectal cancer being the most challenging subtype.

"BOLD-100 has a unique and complex mechanism-of-action and has potential in various challenging cancer subtypes, such as V600E BRAF-mutated colorectal cancer," stated Van Schaeybroeck. "This study further elucidated the mechanism-of-action for BOLD-100 and identified potentially synergistic drug-drug combinations for future investigation."

The AACR (Free AACR Whitepaper) Annual Meeting provides an opportunity to discuss the latest discoveries in cancer research and highlights the work being done by institutions around the world. This year’s virtual conference is taking place April 10-15 and May 17-21.

"Bold Therapeutics has developed a global consortium of world-class academic collaborators to investigate the potential of BOLD-100 as a revolutionary first-in-class anti-cancer agent that targets both ER stress and DNA repair pathways," said Mark Bazett, PhD, Director of Preclinical Development at Bold Therapeutics. "We look forward to connecting with interested researchers at AACR (Free AACR Whitepaper) 2021 to further develop this novel therapy."

Bold Therapeutics is headquartered in Vancouver, British Columbia, Canada. BOLD-100 is currently being investigated in a Phase 1b/2 study in combination with FOLFOX in the treatment of advanced gastrointestinal cancers at six sites in Canada, with additional sites opening in the United States and South Korea in late 2021.

On April 9, 2021 Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, reported Jesse Ledger, Miravo’s President & Chief Executive Officer and Mary-Jane Burkett, Miravo’s Vice President & Chief Financial Officer will be presenting at upcoming investor conferences (Press release, Nuvo Pharmaceuticals, APR 9, 2021, View Source [SID1234580415]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bloom Burton & Co. Healthcare Investor Conference

The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.

Miravo Healthcare Presentation

DATE: Wednesday, April 21st, 2021
TIME: 10:00 a.m. EST
LINK: Conference Registration

Planet MicroCap Showcase

The Planet MicroCap Showcase VIRTUAL EVENT brings together the most promising companies and the top dealmakers in MicroCap Finance for three (3) days of company presentations, 1:1 meetings and educational panels in The Premier Virtual Event in MicroCap Finance.

Miravo Healthcare Presentation

DATE: Thursday, April 22nd, 2021
TIME: 10:00 a.m. EST
LINK: Miravo Presentation

On April 9, 2021 Exscientia, a leading artificial intelligence (AI)-driven pharmatech company, reported the first AI-designed molecule for immuno-oncology to enter human clinical trials (Press release, Exscientia, APR 9, 2021, View Source [SID1234577758]). The A2a receptor antagonist, which is in development for adult patients with advanced solid tumours, was co-invented and developed through a Joint Venture between Exscientia and Evotec, including application of Exscientia’s next generation 3-D evolutionary AI-design platform as part of Centaur Chemist. The drug candidate has potential for best-in-class characteristics, with high selectivity for the target receptor, bringing together potential benefits of reduced systemic sides effects as well as minimal brain exposure to avoid undesired psychological side effects. Preclinical data related to this project will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting to be held 9-14 April, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With this announcement, the company’s AI technologies and drug-hunting expertise are now responsible for the first two AI-designed drugs to enter Phase I testing, following on from Exscientia’s previous announcement in 2020.1

Andrew Hopkins, CEO of Exscientia said, "Immuno-oncology medicines are bringing benefit to a range of cancer patients. Our selective A2a receptor antagonist addresses a next-generation immuno-oncology strategy to empower the human immune system by reversing the effects of high adenosine concentrations. We set ambitious therapeutic objectives for this project, especially high selectivity for the A2a receptor and central nervous system (CNS) sparing properties, in order to reduce the likelihood of systemic side effects. Even with these challenging objectives, we were able to discover our candidate molecule within 8 months of project initiation."

Tumour cells produce high levels of adenosine, a molecule that helps them escape immune system detection by binding to the A2a receptor on cancer fighting T-cells, reducing T-cell ability to eliminate disease.2 Exscientia’s AI-designed A2a receptor antagonist is being investigated for its ability to prevent adenosine from binding to the T-cell receptor and potentially promote anti-tumour T-cell activity.

On April 9, 2021 Biogen Inc. (Nasdaq:BIIB) reported it will report first quarter 2021 financial results Thursday, April 22, 2021, before the financial markets open (Press release, Biogen, APR 9, 2021, View Source [SID1234577794]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. ET. To access the live webcast, please go to the investors section of Biogen’s website at View Source Following the live webcast, an archived version of the call will be available on the website.